Last reviewed · How we verify
Sitosterolemia — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Zetia | EZETIMIBE | Merck & Co. | HMG-CoA Reductase Inhibitor [EPC] | Niemann-Pick C1-like protein 1 | 2002-01-01 | |
| Ezetrol | Ezetrol | NVP Healthcare | Sodium/bile acid cotransporter, Niemann-Pick C1-like protein 1, Niemann-Pick C1-like protein 1 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Merck & Co. · 1 drug in Sitosterolemia
- NVP Healthcare · 1 drug in Sitosterolemia
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Sitosterolemia:
- Sitosterolemia treatment updates — RSS
- Sitosterolemia treatment updates — Atom
- Sitosterolemia treatment updates — JSON
Cite this brief
Drug Landscape (2026). Sitosterolemia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/sitosterolemia. Accessed 2026-06-10.
Related
- Sitosterolemia full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing